Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting SmallSKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR® platform.SKY-0515’s Phase 1 study will inc
Drugging RNASmall molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success. Companies differ...
Drugging RNA with Pills : Small Molecules for a Big FrontierCan biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets? Infused...
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology TargetsCompanies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...
Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfrontPaul Schloesser – Associate Editor, Endpoints A heavily financed biotech looking to drug RNA with small molecules is adding yet another...
Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinicNicole DeFeudis – Editor, Endpoints A few years after becoming one of the first major biotechs out to drug RNA with small molecules,...